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ABSTRACT
Although in situ hybridization has been used to examine the dis-
tribution of messenger RNA for somatostatin receptor subtypes (sst)
in human tumors, the cellular localization of sst1 and sst2A receptors
has not been reported. In this study, we describe the cellular local-
ization of human sst1 and sst2A receptor proteins in both cryostat- and
paraffin-embedded sections of 25 human tumor tissues using two
recently developed polyclonal antibodies. Six somatostatin (SS) re-
ceptor (SSR) positive tumors (two gastrinomas, three carcinoids, one
pheochromocytoma) and one SSR negative tumor (renal cell carcino-
ma), selected by positive and negative SSR autoradiography, respec-
tively, were studied by both immunohistochemistry and Western blot
analysis. The six SSR positive tumors expressed sst2A, while 4 of 5
expressed sst1 as well. The SSR negative tumor did not express either
sst1 or sst2A. Western blot analysis of wheat germ agglutinin purified
membrane proteins confirmed the presence of the sst1 and sst2A gly-
cosylated receptors. The paraffin-embedded sections gave best infor-
mation with respect to the subcellular localization. Sst1 immunore-
activity was observed both on the membrane and in the cytoplasm,
while sst2A showed predominantly membrane-associated immunore-
activity. This subcellular distribution of sst1 or sst2A receptors was
confirmed in paraffin-embedded sections of 8 additional intestinal
carcinoids, 5 gastrinomas and 5 pheochromocytomas. Sst1 receptors
were detected in 7 out of 8 carcinoids, in all gastrinomas, and in 4 out
of 5 pheochromocytomas, while 6 out of 8 carcinoids, all gastrinomas,
and 3 out of 5 pheochromocytomas expressed sst2A receptors. In con-
clusion, sst1 and sst2A receptors show a differential subcellular lo-
calization in human SSR positive tumors. The use of SSR subtype
selective antibodies to detect the subcellular distribution of SSR sub-
types in individual tumor cells is an important step forward to un-
derstand more about the pathophysiological role of the different SSR
subtypes in human tumors. (J Clin Endocrinol Metab 84: 775–780,
1999)
A large number of human neuroendocrine tumors ex-press somatostatin (SS) receptors (SSR) (1). Five SSR
subtype genes, named sst1–5 have been identified and char-
acterized (2). Two isoforms of sst2 (sst2A and sst2B) are gen-
erated by alternative splicing. Until now, the detection of SSR
in human tumors has been performed either by ligand bind-
ing to membrane homogenates or tissue slices to detect com-
bined SSR binding activity, or by messenger RNA (mRNA)
analysis using either in situ hybridization (ISH), RNAse pro-
tection, or reverse transcriptase polymerase chain reaction
(RT-PCR) to detect mRNA for each receptor subtype. While
the use of in vitro SSR autoradiography and ISH has provided
significant information regarding the heterogeneity of SSR
expressed in tumors (1, 3), the precise cellular localization of
SSR’s has been difficult to establish. Recently, two SSR sub-
type specific polyclonal antibodies have been developed (4,
5). The sst1 antibody (code-named R1–201) was raised
against a 15-amino acid peptide corresponding to a unique
sequence in the carboxyl terminus and characterized by im-
munoprecipitation of photoaffinity-labeled sst1 receptor (4).
The sst2A antibody (code-named R2–88) was raised against
a 22-amino acid peptide located in the C-terminal region of
the rat sst2A receptor and characterized by immunoprecip-
tation of photoaffinity labeled sst2A receptor as well as by
immunoblot and immunohistochemistry (IHC) on cells
transfected with complementary DNA encoding sst2A (5, 6).
The peptide sequences used to raise both antibodies are
conserved in the rat, mouse, and human forms (4, 5). The
sst2A antibody has recently been used to detect sst2A in rat
brain, pancreas, and pituitary sections (6–8). In this study we
have used both antibodies to characterize the subcellular
localization of sst1 and sst2A in human neuroendocrine
tumors.
Materials and Methods
Tumor samples
Tumor tissue was obtained immediately after surgical removal and
either frozen in liquid nitrogen through isopentane or fixed in 4% para-
formaldehyde (PF) overnight. Diagnosis was made on the basis of clin-
ical and biochemical characteristics of the patients, in combination with
IHC of the tumor samples. All patients gave their informed consent for
the use of tumor material for research purposes.
Immunohistochemistry
Frozen material. Five-micrometer cryostat sections were air-dried, fixed
for 10 min with 10% PF, washed once with tap water, once with phos-
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phate buffered saline (PBS), and incubated for 15 min in normal goat
serum (1:10 dilution in PBS 1 5% BSA). Thereafter, the sections were
incubated overnight at 4 C with the sst1 (R1–201) and sst2A (R2–88)
antibodies in a dilution of 1:1000. Finally, a standard streptavidin-bio-
tinylated-peroxidase complex (ABC) kit (Biogenix, San Ramon, CA) was
used according to the manufacturers instructions to visualize the bound
antibodies.
Paraffin-embedded material. Five-micrometer sections were deparafinized,
dehydrated, exposed to microwave heating (in citric acid buffer, 10 min
at 100 C), rinsed in tap water (1x) and PBS (1x), and processed further
as described above for the cryostat sections (sst1 and 2A antibody dilu-
tions: 1:500). Negative controls for IHC included omission of the primary
antibody and preabsorbtion of the antibodies with the respective im-
munizing receptor peptides (at a concentration of 0.3 mg/mL 5 100 nm).
Western blot analyis
Membranes were prepared from human tumors or cell lines trans-
fected to overexpress either the rat sst2A receptor (GH-R2) or the rat sst1
receptor (GH-R1) (4–6). Glycosylated proteins were purified by wheat
germ agglutining (WGA) affinity chromatography as previously de-
cribed (8). Either unpurified or WGA-purified membrane proteins were
subjected to electrophoresis on 12% SDS polyacrylamide gels and then
transferred to polyvinylidene difluoride (PVDF) membranes electro-
phoretically (4–6). After blocking, blots were incubated overnight at 4
C with 1:10,000 dilution of the appropiate antibody. Immunoblots were
blocked, washed, and developed as described previously (5–8).
SSR autoradiography
SSR autoradiography was carried out as described previously (9).
Ten-micrometer sections were mounted onto precleaned gelatin coated
microscope slides and stored at 280 C. To wash out endogenous so-
matostatin, the sections were preincubated at room temperature for 10
min in 170 mm Tris-HCl pH 7.4. Thereafter, the sections were incubated
for 60 min at room temperature in 170 mm Tris-HCl pH 7.4, 5 mm MgCl2,
1% BSA, 40 mg/mL bacitracin in the presence of [125I-Tyr3]-octreotide
(about 80–160 pmol/L) or [125I-Tyr0]SS28 (final concentration 80–160
pmol/L; ANAWA Laboratories, Wangen, Switzerland). Nonspecific
binding was determined in a sequential section in the presence of excess
unlabeled Tyr3-octreotide (1 mm) or SS-28 (1 mm). The incubated sections
were washed twice for 5 min in incubation buffer containing 0.25% BSA
and once in incubation buffer without BSA. After a short wash with
distilled water to remove salt, the sections were air dried and exposed
to Kodak X-OMAT AR or HyperfilmTM-3H (Amersham, Buckingham-
shire, United Kingdom) for 3–7 days in x-ray cassettes. Histology was
performed on hematoxylin-azophloxine stained sequential cryosections.
Results
Seven human neuroendocrine tumors of different origin
were selected on the basis of positive and negative SSR au-
toradiography (Table 1). Figure 1 shows the localization of
sst1 (Fig 1, A, B, E) and sst2A receptors (Fig. 1, C, D, F) in a
human gastrinoma. For sst1 receptors immunohistochemical
staining was observed both in the cytoplasm and at the cell
membrane. This was seen most clearly in the paraffin-em-
bedded sections (1B). Sst2A receptors were preferentially lo-
calized at the cell membrane (1D). Both intestinal carcinoids
examined by IHC-expressed sst1 and all three carcinoids
tested expressed sst2A (Table 1). The other gastrinoma ex-
pressed sst2A as well. The localization of sst1 receptors in the
sst1-positive carcinoid was primarily cytoplasmic as well
(1G). In addition, mainly membrane-localized sst2A receptors
were found in the pheochromocytoma (1H). The pheochro-
mocytoma was slightly sst1 positive as well. Neither sst1 nor
sst2A immunostaining was observed in the stromal compart-
ment of any of the tumors, although the endothelial cells of
some tumoral vessels were sst2A positive (not shown). The
renal cell carcinoma, which was selected on the basis of
negative SSR autoradiography using [125I-Tyr0]somatostatin-
28 and [125I-Tyr3]octreotide showed no positive staining by
either the sst1 and sst2A antibody (Table 1).
To enrich the tumor extracts for the glycosylated receptor
proteins, solubilized membrane proteins were partially pu-
rified by WGA-affinity chromatography before immunoblot-
ting. Figure 2 compares the results of the sst1 and sst2A
analysis in a gastrinoma and an intestinal carcinoid to the
staining observed in an SSR negative pituitary cell line
(GH12C1) transfected to express either sst1 and sst2A. In each
case, the most darkly stained band shows the broad migra-
tion pattern and size range characteristic of sst receptors.
Immunostaining of this band was completely inhibited by
0.5–1 mm antigen peptide (Fig. 2). Data from all tumors ex-
amined are summarized in Table 1. The apparent molecular
weight (Mw) for each receptor subtype varied between tu-
mors: the observed Mw for sst1 ranged from 45 to 80 kDa,
whereas that for sst2A varied from 60 to 85 kDa. This vari-
ability is consistent with differential glycosylation occuring
in individual tumors and resembles what was previously
observed in tumor cell lines (4–5) and rat tissues (6–8).
To further confirm the differential subcellular localization of
sst1 and sst2A receptors in the tumor cells, we performed im-
munohistochemical analysis of both receptor subtypes in par-
affin-embedded sections of eight additional intestinal carci-
noids, five gastrinomas, and five pheochromocytomas. Sst1
receptors were detected in seven out of eight carcinoids, in all
gastrinomas (n 5 5), and in four out of five pheochromocyto-
mas. Positive immunostaining for sst2A receptors was found in
6 out of 8 carcinoids, in all gastrinomas (n 5 5), and in three out
of five pheochromocytomas. This is shown in Table 2. In all
TABLE 1. SSR subtype sst1 and sst2A expression in human tumors as determined by SSR autoradiography, immunohistochemistry
(IHC), and Western blotting
Number Tumor type
SSR autoradiography IHCa Western blotting
SS-28 T3O sst1 sst2A sst1 sst2A
1 Gastrinoma nt 1 1 1 nt 1
2 Gastrinoma 1 1 nt 1 1 1
3 Pheochromocytoma 1 1 6 1 2 1
4 Intestinal carcinoid 1 1 1 1 1 1
5 Intestinal carcinoid 1 1 1 1 1 1
6 Intestinal carcinoid 1 1 nt 1 2 1
7 Renal cell cancer 2 2 2 2 2 2
nt, not tested; 2, negative; 6, weakly positive; 1, positive. SS-28: [125I-Tyr0]SS-28, T3O: [125I-Tyr3]octreotide.
a IHC in cryostat- and/or paraffin-embedded sections.
776 HOFLAND ET AL. JCE & M • 1999
Vol 84 • No 2
tumors specificity of the staining with the sst1-specific antibody
(R1–201) and with the sst2A-specific antibody (R2–88) was con-
firmed by the abolishment of immunostaining when the anti-
bodies were pre-absorbed with 100 nm of the respective im-
munizing peptides. Figure 3 shows examples of the
neutralization of the predominant cytoplasmic staining for sst1-
receptors in an intestinal carcinoid (Fig. 3, A, B) and in a gas-
trinoma (Fig. 3, C, D), as well as for the predominant mem-
FIG. 1 Localization of sst1 and sst2A subtypes in a human SSR positive tumors. Immunohistochemical detection of sst1 (R1–201 antibody) and
sst2A (R2–88 antibody) using two recently developed polyclonal antibodies (4–8) in human neuroendocrine tumors. A-D, gastrinoma, paraffin-
embedded sections; E-F, gastrinoma, cryostat sections (A, B, E: sst1, C, D, F: sst2A). G; sst1 immunoreactivity in paraffin-embedded section of
a human carcinoid; H, sst2A immunoreactivity in paraffin-embedded section of a human pheochromocytoma. Note the primarily cytoplasmic
immunohistochemical localization of sst1 and the preferentially membrane-associated sst2A immunoreactivity.
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brane-associated staining of sst2A-receptors in a gastrinoma
(Fig. 3, E, F) and a pheochromocytoma (Fig. 3, G, H). In the
tumors studied, irrespective of the tumor type, we confirmed
the primarily cytoplasmic localization of sst1 receptors and the
preferential localization of sst2A receptors at the cell membrane.
Discussion
Along with the widespread actions of SS, many SS-target
tissues as well as many neuroendocrine tumors often orig-
inating in these target tissues, have been shown to express
SSR’s (1, 10). Until now SSR detection has been performed
using ligand binding studies on membrane preparations or
on frozen sections. In addition, the recent cloning and char-
acterization of the genes of five SSR subtypes (2) has pro-
vided molecular biological tools, i.e. RT-PCR and ISH tech-
niques, to study SSR subtype expression in normal and
tumoral tissues (3). Moreover, the development of SSR sub-
type specific antibodies (4–8) now allows a detailed study of
the cell types and cellular localization of SSR subtype pro-
teins. In the present study we describe the cellular localiza-
tion of sst1 and sst2A receptors in human neuroendocrine
tumors of different origin. Specificity of the sst1 and sst2A
antibodies was confirmed by immunohistochemical identi-
fication of approximately 60 and 85 kDa receptor proteins,
respectively, in tumors by Western blotting experiments. The
high frequency of expression of sst1 and sst2A receptor pro-
teins in gastrinomas and carcinoids is in agreement with a
predominant expression of sst1 and sst2A mRNAs in these
tumor types (11).
The presence and possible functional significance of SSR’s
and SSR subtypes expressed in normal and tumoral neu-
roendocrine tissues has been reviewed (2, 10, 12). While sst2A
and sst5 are involved in the inhibition of hormone secretion,
the functional role of the other SSR subtypes is less clear. In
cells transfected with SSR subtype genes, agonist activation
of sst1, sst2A, and sst5 seems involved in the antiproliferative
action of SS(-analogs) via distinct as well as overlapping
mechanisms (2). Whether such mechanisms also occur in
human tumor cells expressing these particular subtypes re-
mains to be established.
In the present study we found immunoreactive sst1 pri-
marily in the cytoplasm, whereas sst2A was predominantly
expressed at the cell membrane, irrespective of the tumor
type. The membrane-localization of sst2 is in agreement with
a recent study by Janson et al. (13) in human carcinoid tu-
mors. The precise functional significance of our observations
is unclear. The cytoplasmic sst1 may represent either neo-
synthesized or internalized receptors, as suggested previ-
ously to explain the cytoplasmic localization of sst2A in spe-
cific rat brain neurons in regions with high somatostatin
expression (14). However, previous studies with COS or
CHO cells transfected with individual SSR subtypes have
shown that sst1 is internalized more poorly than sst2A after
hormone binding (15, 16). If endogenous receptors in tumors
behaved similarly, one would predict that more of the sst2A
than the sst1 receptor would be internalized in tumors ex-
pressing both receptor subtypes. Instead we found the in-
verse distribution. Moreover, agonist exposure upregulates
sst1 expression in CHO-K1 cells expressing this SSR subtype
(16), while chronic SS exposure of GH4C1 pituitary cells in-
creases SSR numbers (17). This increase in SSR number in
GH4C1 cells was independent of new protein synthesis, and
a potential mechanism could be changes in the intracellular
distribution of SSRs (17). In this respect our observation of a
predominant cytoplasmic localization of sst1 receptors in
human tumor cells may also reflect a capacity of the tumor
cells expressing this SSR subtype to increase SSR numbers
after agonist exposure. This suggests that treatment of sst1
receptor-expressing cells with sst1-selective agonists may not
FIG. 2. Immunoblot analysis of sst1 and sst2A in human tumors. Ei-
ther unpurified membrane protein (GH-R2 cells, 5 mg) or WGA-pu-
rified membrane proteins (GH-R1 cells, gastrinoma, or carcinoid,
purified from 35 mg, 300 mg, and 100 mg of membrane protein, re-
spectively) were separated on a 12% SDS polyacrylamide gel. After
transfer to polyvinylidene difluoride (PVDF) membrane, the proteins
were immunoblotted with 1:10,000 dilution of sst1- (R1–201) or sst2A
(R2–88) antibody in the absence (2) or presence (1) of either 1 mM sst1
peptide or 0.5 mM sst2A peptide antigen. Mw markers (in kDa) are
shown on the left.
TABLE 2. Immunohistochemical detection of SSR subtypes sst1
and sst2A in paraffin embedded sections of human neuroendocrine
tumors
Number Tumor type
SSR subtype
sst1 sst2A
8 Intestinal carcinoid 1 1
9 Intestinal carcinoid 1 2
10 Intestinal carcinoid 2 2
11 Intestinal carcinoid 1 1
12 Intestinal carcinoid 1 1
13 Intestinal carcinoid 1 1
14 Intestinal carcinoid 1 1
15 Intestinal carcinoid 1 1
16 Gastrinoma 1 1
17 Gastrinoma 1 1
18 Gastrinoma 1 1
19 Gastrinoma 1 1
20 Gastrinoma 1 1
21 Pheochromocytoma 2 2
22 Pheochromocytoma 1 1
23 Pheochromocytoma 1 1
24 Pheochromocytoma 1 2
25 Pheochromocytoma 1 1
For immunohistochemical detection, two recently developed sst1
(R1-201) and sst2A (R2-88)-specific polyclonal antibodies were used
(4–6)
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FIG. 3. Displacement of immunohistochemical staining of sst1 (R1–201 antibody) and sst2A (R2–88 antibody) subtypes in human SSR positive
tumors by preabsorbtion of the antibodies with 100 nM of the respective immunizing peptides. A and B, intestinal carcinoid (sst1); C and D,
gastrinoma (sst1); E and F, gastrinoma (sst2A); G and H, pheochromocytoma (sst2A).
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result in a desensitization to treatment as has been observed
in the majority of patients with islet-cell tumors and carci-
noids treated with sst2-selective octapeptide SS-analogs (18).
Clearly additional studies will be needed to establish
whether this differential localization of sst1 and sst2A is a
general phenomenon and to determine the biochemical
mechanisms responsible.
In summary, the use of SSR subtype specific antibodies
now allows a detailed examination of the subcellular local-
ization of SSR subtypes in individual cells. This is an im-
portant step toward understanding more about the func-
tional role of the individual SSR subtypes in human SSR
positive tumors.
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